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Abstract
Objective: To analyse our experience with excision of lung metastases from colorectal carcinoma (CRC), and to evaluate clinically relevant
prognostic factors, identifying the cluster of patients who would benefit from this procedure. Methods: Sixty-one patients, 42 men (69%), with
primary CRC who underwent 94 curative resections of pulmonary metastases were retrospectively reviewed. Age was 30—80 years (mean
61.2  15). Population was analysed for age, sex, disease-free interval (DFI), prethoracotomy carcinoembryonic antigen (CEA) level, location and
histology of primary tumour, number of lung lesions (and size of largest resected metastasis), type of lung resection, nodal involvement (hilar/
mediastinal), use of adjuvant treatment, morbid-mortality and immediate and follow-up survival. Results: Mean DFI was 29  22 months (range
5—132 months). There was no hospital mortality and significant morbidity occurred in five patients (8.2%). Mean follow-up was 39  4 months
(range 4—173 months). Mean overall survival and disease-free survival were 67  16 months and 52  6 months, respectively. Three-, 5- and 10-
year survival rates from date of primary colorectal resection were 83%, 71% and 43%, respectively. Three-, 5- and 10-year survival rates from date
of lung resection were 61%, 48% and 11%, respectively. Five-year survival was 57% in patients with normal prethoracotomy CEA levels and 18% for
those with high levels (>5 ng/ml) ( p = 0.039). Conclusions: Pulmonary metastasectomy has potential survival benefit for patients with
metastatic colorectal carcinoma. Low morbidity and mortality rates, contrasting with lack of any other effective therapy, justify aggressive
surgical management. Single deposits, DFI >36 months and normal prethoracotomy serum CEA were significant independent prognostic factors.
# 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Second only to lung cancer in men and breast cancer in
women, colorectal cancer is an important cause of death,
with increasing incidence over the past 25 years [1—3]. The
lung is one of the most frequent sites of metastatic
dissemination of colorectal carcinoma (CRC), which affects
10—25% of all patients [4—6]. Since Blalock reported the first
successful removal of a pulmonary metastasis, in 1944, and,
later, Thomford reported the principles of surgical resection
of lung metastases, the procedure has been gradually
accepted as a treatment with proven value if the metastatic
process is confined to the lungs [4,6—8].
But while resection of solitary lung metastases has been
well accepted by physicians, metastasectomy for multiple
or bilateral lesions remained controversial until recently
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number of patients has undergone repeated thoracotomy
for recurrent lung metastases [9,10]. Operative indications
must be considered from all points of view, as the lung
metastasis is a distant lesion and pulmonary resection
always causes a decrease in respiratory function. Hence, it
is useful to identify the patients who can benefit from
surgery [4]. The number of possible candidates for
resection of lesions has increased in the last two decades
and indications for excision and prognostic factors have
been continuously reviewed. Earlier detection of lung
metastases as small peripheral densities with spiral or high-
resolution computed tomography (CT) favour the increased
demand for surgical treatment [10].
We have previously published the results of surgical
resection of lung metastases from osteogenic sarcomas and,
more recently, from epithelial tumours [8,11]. The aim of
the current study was to analyse our experience with
excision of lung metastases from colorectal carcinoma and
to evaluate clinically relevant prognostic factors, establish-
ing the cluster of patients who may potentially benefit from
this procedure.urgery. Published by Elsevier B.V. All rights reserved.
N. Rama et al. / European Journal of Cardio-thoracic Surgery 35 (2009) 444—449 4452. Material and methods
2.1. Patients
A total of 61 consecutive patients with primary colorectal
carcinoma, including 30 colon cancers (49%) and 31 rectal
cancers (50%), underwent 94 curative pulmonary resections
for suspected lung metastases, at our centre, between
January 1988 and December 2005. Forty-two (69%) of the 61
patients were men and the age ranged from 30 to 80 years
(mean with standard deviation, 61  14 years).
Only patients in whom all the macroscopic lesions
secondary to colorectal carcinoma could be and were excised
(‘curative’ surgery) were included in this study, Patients who
had palliative lung metastasectomy from colorectal carci-
nomas were not considered. Our criteria for curative surgical
resection included either unilateral or bilateral excisable
lung lesions, as per preoperative chest radiography and CT
scan, with no local recurrence of primary lesions and absence
of extrapulmonary lesions, except prior resectable hepatic
metastases. Patients who had synchronous metastases were
operated firstly for the hepatic metastases and 3 weeks later
were operated on the lung. We never performed metasta-
sectomy at the same time in liver and lung. Patients with
other extrapulmonary metastases should be controlled
before any surgical pulmonary procedure. All patients should
be able to tolerate the degree of lung parenchyma excision
envisaged.
The surgical decision was made jointly by the thoracic
surgeon and the medical oncologist and/or general surgeon.
The clinical decision about the use of neo-adjuvant or
adjuvant therapy was made by the oncologist. A full
preoperative metastatic work-up was undertaken in the
referring departments. Physiologic assessment, including
pulmonary function studies (with arterial blood gases), were
carried on all 61 patients. All patients were judged to be at
low preoperative risk for the procedure.
Cancer of the colon had occurred in the ascending portion
and caecum in 12 cases (20%), in the transverse colon in one
patient, in the descending colon in six (10%) and in the
sigmoid in 11 cases (18%). Rectal carcinomas were located in
the lower third in 11 cases, in the middle portion in 12
patients and in upper third in the remaining 8 cases.
2.2. Surgery
All patients were operated on by lateral thoracotomy. We
have routinely conducted a careful palpation of inflated-
deflated lung tissue [25], allowing resection of all suspicious
lesions, including those not detected by preoperative CT
scan. Macroscopically involved lymph nodes were resected.
The surgical approach was chosen according to the location
and number of pulmonary lesions and the type of lung
resection ranged from wedge resection to various types of
anatomic lung resection. We attempted to preserve the
maximum amount of functioning lung tissue, with 5—10 mm
tumour-free margins. Lobectomy or other ‘major’ procedure
was performed when lesser resection did not allow a R0
excision in frozen sections, or when in doubt between
primary bronchial adenocarcinoma and metastasis. Lung
metastasectomy was considered complete, hence curative,if all known intrathoracic cancer was removed, with
histologic-proven tumour-free margin.
2.3. Statistical analysis
All medical records were reviewed and all patients
contacted directly or by telephone. For each patient, clinical
and pathological features were recorded. Patients were
evaluated for location and histology of the primary tumour,
disease-free interval (DFI), number of lung lesions, size of
largest resectedmetastases, prethoracotomy carcinoembryo-
nic antigen (CEA) level, type of lung resection, nodal
involvement (hilar ormediastinal), use of adjuvant treatment,
morbid-mortality and immediate and follow-up survival.
Disease-free interval was calculated from the date of
curative surgical treatment of colorectal cancer to the date
of diagnosis of lung metastases. Survival was calculated from
the time of first lung metastasectomy to the last date of
follow-up. All available data were updated in September
2007 (minimum follow-up gap of 12 months). Statistical
calculations were carried out with MedcalcW software version
7.6.0.0 (1993—2005, Frank Schoonfans, Belgium). Actuarial
survivals were analysed by the Kaplan—Meier method. All
variables that by univariate analysis revealed a statistically
significant difference were entered into the multivariate
analysis. A probability value of 0.05 or less was considered
statistically significant.3. Results
3.1. Clinical and surgical
Data available on the 61 patients are summarised in
Table 1. The diagnosis of lung lesions was made by chest
radiography in 36 patients (59%), almost two thirds of this
before 1995, due to lack of availability of CT scan in the
hospital. In the remaining 25 patients (41%), it was made by
CTscan, now regularly used in the follow-up of patients with
colorectal cancer.
Histology of the primary tumour included 51 well-
differentiated neoplasms (83%) and 10 moderately to poorly
differentiated tumours. In 55 cases, the primary tumour
stage was accessible (91%). Only two patients displayed
limited tumour stages (stage I of TNM/UICC; pT1—2, pN0).
The majority were operated on in advanced stages.
Among the study patients, the mean DFI was 29.1 months
(SD, 22,4) and ranged from 5.2 to 132 months. Almost three
fourths of the cases were asymptomatic, and the remaining
15 cases showed cough in 6, dyspnoea in 5, haemoptysis in 3
and pain in 2.
At the operation for metastasectomy, the right lung and
the lower lobes were affected in the majority of cases (59% —
36 patients, in both situations). Thirty-seven cases (61%) had
a single metastasis, and the mean number of lesions was
1.6  0.8. Forty-four patients (72%) had metastases with
diameter smaller than 3 cm. Hilar or mediastinal nodal
involvement was macroscopically and histologically con-
firmed in seven cases (11%).
In total, 94 thoracic procedures were performed in the 61
patients. The surgical approach was chosen according to the
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Table 1
Clinical data.
Variable N %
Age (years, mean and age limits) 61.2 (30—80)
Sex
Male 42 68
Female 19 32
Primary tumour location
Colon 30 59
Rectum 31 61
DFI
36 months 41 67
>36 months 15 33
Lung nodules (N)
1 37 61
2 13 21
3 11 18
Affected lung
Right 36 60
Left 23 37
Bilateral 2 3
Diameter of lung nodules
3 cm 44 72
>3 cm 17 28
Approach
Thoracotomy
Unilateral 79 84
Bilateral 14 15
Sternotomy 1 1
Resection
Wedge 73 78
Lobe 16 17
Others 5 5
Chemotherapy
Preoperative 2 3
Postoperative 42 69
None 17 28
Fig. 1. Kaplan—Meier survival curve, from date of lung metastasectomy.
Fig. 2. Kaplan—Meier survival curve from date of primary colorectal resection.location and number of lung lesions. Most frequently (79
cases; 88%), the procedure was performed through standard
unilateral posterolateral thoracotomy. A median sternotomy
was used in one patient and staged bilateral thoracotomy in
the remainder (12%). Wedge resection was the procedure of
choice, trying to preserve normal lung parenchyma as much
as possible. This surgical procedure was done in 73 cases
(78%). Other surgical procedures were lobectomy in 16
patients, enucleation plus lobectomy, or enucleation alone in
two patients each, and pneumectomy in one patient.
Chemotherapy was administrated in 44 patients (72%)
withmetastases, as adjuvant (42 patients) or neo-adjuvant (2
patients) treatment.
3.2. Perioperative results and survival
There was no hospital mortality in this series. Significant
perioperative morbidity occurred in five patients (8%),
including two bronchopleural fistulae (controlled withchemical pleurodesis), and acute renal insufficiency, hae-
morrhage, wound infection (one patient each). Follow-up
was complete on September 30, 2007, or to death, for 56 of
61 patients (92%). The remaining five patients were excluded
from statistical analysis, because all connections to the
hospital were lost after surgery. Mean follow-up was 39  37
months, ranging from 4 to 173 months.
Metastatic disease recurred in 36 patients (64%), 8 were
alive at the time of follow-up (14%) and 28 (50%) died
because of progressive disease. Recurrence was limited to
the lung in one third of patients (12 cases), the abdomen in
5 (14%), the brain, bone or other locations in 1 patient
each. Relapse occurred in multiple organs in 16 patients
(44%), 14 of whom had lung involvement. Altogether,
pulmonary relapse occurred in 26 patients, 72% of those
with recurrence. Eighteen patients (32%) were alive
without any sign of relapse and 2 patients died of
unrelated causes. Mean survival and disease-free survival
were 67  16 months and 52  6 months, respectively.
Overall, 3-, 5- and 10-year survival rates, from the date of
lung resection, were 61%, 48% and 11%, respectively
(Fig. 1). Overall, 3-, 5- and 10-year survival rates, from the
date of primary colorectal resection, were 83%, 71% and
43% respectively (Fig. 2).
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Fig. 4. Kaplan—Meier survival curve related to preoperative CEA serum level.
Group A: CEA 5 ng/ml; group B >5 ng/ml. Log-rank test (p = 0.0389).
Table 2
Potential prognostic factors tested by univariate analysis.
Factor p value
Sex 0.505
Primary location 0.307
DFI (6 vs >36 months) 0.045
Histological type 0.013
pTNM/UICC stage 0.045
Affected lung 0.022
Lung lesions
Single/multiple 0.042
Number 0.053
Diameter 0.050
Symptomatic status 0.202
Complications 0.260
Adjuvant chemotherapy 0.017
Relapse of lung metastases 0.030
Prethoracotomy CEA 0.0383.3. Analysis of risk factors for survival
The potential prognostic factors analysed are shown in
Table 2. Of these factors, sex, location of the primary tumour,
symptomatic status, the number and size of lung metastases,
nodal involvement and postoperative complications did not
significantly influence survival.
Five-year DF-survival rates, considering the definition of
DFI used in by the International Registry of Lung Metastasis
and adopted by other authors [8,14,15], were 51% and 92%,
respectively for patients who had DFI of up to 35 months
versus 36 months or more, and this observation was
statistically significant ( p = 0.046; Fig. 3).
We also analysed survival according to the grade of
differentiation of the tumour and the TNM/UICC stage, as
defined during surgery for the primary colorectal lesion. Five-
year survival rates for patients of grade G1 versus grades G2—
4 were 88% and 43%, respectively ( p = 0.013). Concerning
TNM/UICC stage, the 5-year survival rates were 56% and 32%,
respectively for patients with stages II and III ( p = 0.045).
The number of stage I cases was too small for comparative
analysis.Fig. 3. Kaplan—Meier survival curve, according to the DFI: DFI 36 or >36
months. Log-rank test ( p = 0.0457).Patients with solitary lung lesions had a better long-term
survival than those with multiple nodules. Three- and 5-year
survival rates were 66% and 57% for the former and 53% and
27% for the latter ( p = 0.043). Finally, the 5-year survival rate
in patients submitted to adjuvant chemotherapy was 70%,
versus 29% in those who had not ( p = 0.017).
Among the study patients, those without recurrence of
lung lesions after first metastasectomy had a 5-year survival
of 63% as compared with 38% for the subgroup with relapse
( p = 0.031).
Prethoracotomy CEA levels were measured in 53 patients
(95%), and the 5-year survival rate was 57% for 31 patients
with normal prethoracotomy CEA levels and 18% for the
remainder with high (5 ng/ml) levels ( p = 0.039; Fig. 4).
A multivariate analysis was carried out including all
variables which revealed a statistically significant difference
by univariate analysis. The results are shown in Table 3.
Serum prethoracotomy CEA levels and solitary versus
multiple lung lesions were the covariate factors of poor
prognosis for patients ( p = 0.006 and p = 0.014, respec-
tively). Histological type or grade of primary tumour was not
an indicator of poor prognosis, but tended towards
significance ( p = 0.051). The other factors were not found
significant.
Patients were arbitrarily divided into three groups
according to the presence or absence of the abovementioned
prognostic factors: group I — patients with single metastasis,
DFI >36 months, CEA 5 ng/ml; group II — patients with
singlemetastasis and DFI36months or CEA>5 ng/ml; group
III — patients with single or multiple metastasis, DFI 36Table 3
Potential prognostic factors by multivariate analysis.
Variables Hazard ratio 95% CI p value
CEA level (<5 ng/ml; elevated) 3.762 0.382—2.267 0.0061
DFI a 0.438 0.096—1.746 0.0807
Histological differentiationb 0.212 0.001—3.106 0.0510
pTNM/UICC stage 1.277 0.513—1.002 0.5296
Solitary versus multiple lesions 0.316 0.236—2.068 0.0142
CI: confidence interval.
a Disease-free interval (36 months or >36 months).
b Grade 1 or 2—3, of primary colorectal cancer.
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Fig. 5. Kaplan—Meier survival curve related to the presence of risk factors.
Groups I—III (see text). Log-rank test ( p = 0.0066).months and CEA >5 ng/ml; The 3- and 5-year survival rates
were 81% and 71%, respectively, for the first group (I), and
29% and 15%, respectively for the second group. None of the
patients in the third group were alive after 41 months
( p = 0.007; Fig. 5).4. Comment
According to recent statistics, colorectal cancer is the
second most frequent malignancy in Portugal, with an
incidence similar to breast cancer in women and higher than
cancer of the prostate in men, and contributes to 15% of total
oncologic mortality. In Europe in 2004, an estimated 197,200
men were diagnosed with colorectal cancer, representing
13% of new cancer cases. In the same year, colorectal cancer
was diagnosed in approximately 179,200 women, represent-
ing 13% of new cancer cases and making it the second most
common incident form of cancer in women (http://
www.eurekalert.org/pub_releases/2005-11/foec-
cfi110205.php, accessed 17 June 2008). However, the death
rate from colon cancer has declined over the past 15 years
due to improved screening methods and advances in
treatment [12,13].
Common sites of metastisation from colorectal cancer
include liver and lung, with bone and brain metastasis
occurring infrequently (approximately 6% and 1%, respec-
tively) [14]. Therapeutic advances for patients with meta-
static colorectal carcinoma have been associated with
prolonged survival and this fact is associatedwith an increased
incidence of metastases at uncommon sites [14,15]. But, to
date,noeffectivechemotherapeutic, fully curative treatment
is available and, consequently, resection of lung lesions has
been accepted as appropriate therapy by most surgeons
[9,16—19]. In recent years, we have been referredmany cases
of lung metastases from colorectal adenocarcinoma because
early screening with highly efficient CT scan (helical or high-
resolution) made diagnosis more accurate and more timely.
Therefore, it seems appropriate to evaluate the prognostic
factors for this population.
Until recently, general criteria for pulmonary metasta-
sectomy from colorectal carcinoma were not consensually
established, but several studies favour lung metastasectomyin all patients with potentially resectable metastases, no
residual tumour at the primary site, no extrathoracic disease
and ability to tolerate the degree of lung resection
envisaged. Several authors consider that multiple and
bilateral lesions are not a contraindication for lung resection,
as long as they are completely excised. However, synchronic
lung nodules had significantly lower survival than metachro-
nous lesions [20].
Some authors defended that there is no considerable
influence in survival rates related to multiple lesions,
number, size, tumour location or bilaterality of lung nodules
[4,8]. We found that cases with solitary lung lesions had a
significantly better survival rate than those with multiple
metastases, both by univariate and multivariate analysis. On
the other hand, Iizasa [10], and Okumura [21] and their co-
authors reported that the number and size of pulmonary
nodules were independent prognostic factors. We believe
that an accurate preoperative staging with lung CT scan,
correctly evaluating the number and size of nodules, may
have an influence on prognosis, becoming progressively more
important in the diagnosis and therapy planning.
Human CEA expression, a member of CEA-related cell
adhesion molecule family, is associated with progression of
colorectal cancer, and was the most widely used human
tumour marker [22]. Several investigators have analysed
preoperative CEA as a prognostic factor after lung metas-
tasectomy. The majority of the results demonstrated that
prethoracotomy serum CEA was one of the most significant
prognostic factors [7,9,24]. In this study, the preoperative
serum CEA level was the most useful prognostic indicator for
survival after metastasectomy, in both univariate and
multivariate analyses. We assume that this factor could be
one of the important indicators of dissemination of colorectal
adenocarcinoma because elevated CEA expression is asso-
ciated with poorer prognosis of either primary or metastatic
colorectal cancer. Although Bcl-2 and galactin-3 are now
commonly used as tumour markers, they were not available
at time of this study.
We also suggest both the pTNM stage and the grade of
differentiation of the primary tumour as reference factors for
metastasectomy. Dukes classification or, more currently,
pTNM/UICC stage has been reported to be a prognostic factor
for patients undergoing hepatic metastasectomy for color-
ectal cancer [4,5,23], but the prognostic impact of Dukes
stage in patients with pulmonary metastasis has not been
sufficiently assessed. Nonetheless, Inoue [4] and Lucena [5]
and their co-workers demonstrated that the Dukes/pTNM
stage is an independent prognostic indicator. We also found
the pTNM/UICC stage to be a statistically significant factor by
univariate analysis, although this could not be confirmed by
multivariate analysis. It may, however, suggest this indicator
as a useful prognosis predictor, and it should be considered
for operative indication in these patients. Only one other
study, published by Ike et al. in 2002, found statistical
significance related with the grade of differentiation of the
primary growth [24].
From the classification in the three groups we defined
above, we can conclude that patients with single nodules
that are completely respectable, with DFI >36 months and
normal prethoracotomy serum CEA levels have the best
results after lung metastasectomy from colorectal cancer.
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without these favourable prognostic factors should not be
denied resection.
In our experience, a limited wedge resection remains the
procedure of choice for metastasectomy, permitting a R0,
curative therapy. There was no operative mortality, and
this approach was associated with very low perioperative
morbidity. Several studies concerning lung metastasectomy
from colorectal carcinoma reported 5-year survivals ranging
from 21% to 63%, and most were around 40% [7—9,21,24,25].
Our overall 5-year survival rate was 48% from the time of lung
resection and 71% from the time of surgery of the primary
carcinoma.
In conclusion, our experience appears to indicate that
pulmonary metastasectomy carries a potential survival
benefit for patients with metastatic colorectal carcinoma.
Low morbidity and mortality rates, parallel with the lack of
any other effective therapy, justify the aggressive approach
of surgical management. Resections should be carried out
preserving maximal normal lung parenchyma, which could
allow a safer re-excision, if necessary. Single deposits, DFI
>36 months and normal prethoracotomy serum CEA levels
were significant independent prognostic factors for medium-
term survival.
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Appendix A. Conference discussion
Dr F. Carnochan (Edinburgh, Scotland): The patient that came with
metastasis after about 10 years, how convinced was the pathologist that it was
definitely a metastatic lesion and not a possible primary lung adenocarcinoma?
Dr Calvinho: This patient had a raised CEA level and we performed a fresh
frozen section of the nodule and it was proved during surgery that it was a
metastasis of colorectal cancer.
Dr Carnochan: And did they have a colonoscopy prior to their surgery?
Dr Calvinho: Everything was OK.
Dr A. Oliaro (Torino, Italy): In our department, now we associate with a
lymphadenectomy. What is your opinion about lymphadenectomy to remove
the metastases?
Dr Calvinho: We do not routinely perform lymphadenectomy. We only
perform lymphadenectomy for microscopic nodules that we can find during
surgery or preoperatively. In this series, 12% of patients had lymphadenectomy
during surgery.
